Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.

Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.